Edward P Acosta

发表

Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors

Hulin Wu, Yangxin Huang, Edward P Acosta, 2010, Biometrical journal. Biometrische Zeitschrift.

Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline

Michael S Saag, Edward P Acosta, Anju Bansal, 2008, AIDS.

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study

Catia Marzolini, Edward P Acosta, D. Clifford, 2004, AIDS.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2006, JAMA.

Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals

Hulin Wu, Song Yu, Edward P Acosta, 2004, Journal of acquired immune deficiency syndromes.

Comparison of Two Strategies for Administering Nevirapine to Prevent Perinatal HIV Transmission in High-Prevalence, Resource-Poor Settings

Edward P Acosta, Moses Sinkala, J. Stringer, 2003, Journal of acquired immune deficiency syndromes.

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Edward P Acosta, Victoria A Johnson, Daniel R Kuritzkes, 2008, The Journal of infectious diseases.

Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance

Hulin Wu, Edward P Acosta, Daniel R Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

Marylyn D Ritchie, Gene D Morse, Benjamin J. Grady, 2012, Pharmacogenetics and genomics.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2004, The New England journal of medicine.

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

Lin Shen, Yan Zhou, Susan Peterson, 2008, Nature Medicine.